论文部分内容阅读
Objective:The aim of the study was to evaluate the ef icacy and safety of cytokine-induced kil er (CIK) cellcombined with transcatheter arterial chemoembolization (TACE) therapy in the treatment of hepatocellular carcinoma (HCC). Methods:Randomized control ed trials (RCTs) on CIK cells combination with TACE based-therapy were identified by elec-tronic searches in the Cochrane Library, MEDLINE, Pubmed, Wanfang, VIP, CNKI and other electronic databases. We in-cluded any RCTs evaluating CIK cellcombination with TACE for the treatment of hepatocellular cancers. The quality of RCTs meeting inclusion criteria was evaluated and data on short-term and long-term curative ef ects, quality of life, liver function and immunologic function were extracted. For quantitative data, we conducted meta-analysis with ReMan 5.1 software and the GRADE System was used to rate the level of evidence and strength of recommendation. For qualitative data, data mainly adopted descriptive methods. Results:The 9 RCTs involving 870 cases meeting the inclusion criteria were included. The meta-analysis showed significant survival benefit on 0.5-year survival rate (RR=1.51, 95%CI, 1.35-1.69, P